The global oncology molecular diagnostics market size was US$ 2450 Million in 2021. The global oncology molecular diagnostics market size is forecast to reach US$ 6450 million by 2030, growing at a compound annual growth rate (CAGR) of 12.2% during the forecast period from 2022 to 2030.
Oncology is a branch of medicine that deals with cancer prevention, diagnosis, and treatment. A molecular diagnosis involves identifying a disease by analyzing the molecular components of tissue or fluid, such as proteins, DNA, and RNA. The detection of specific DNA or RNA sequences that may or may not be associated with the disease may include single nucleotide polymorphisms (SNPs), deletions, rearrangements, and insertions, which help to diagnose and predict infections, cancer, and other genetic disorders.
Factors Influencing Market Growth
Impact Analysis of COVID-19
COVID-19 has significantly affected the oncology molecular diagnostics market. According to the Association for Molecular Pathology (AMP), a survey of 163 laboratories conducted in April-June 2020, 85% of the respondents reported that molecular testing for cancer had decreased. More than half of respondents also said oncology testing for clinical trials had decreased due to lower enrollment, reluctance to travel, and the ability to conduct testing. In addition, the survey results suggest that the pandemic may continue to negatively affect molecular diagnostic testing for cancer for years to come. Additionally, laboratories and universities engaged in cancer research and development have experienced a halt in activities. Furthermore, government funding from various organizations is on hold in several countries.
Regional Insights
The North America market accounted for most industry revenue in 2021, followed by European markets. Due to the well-established healthcare infrastructure, a growing number of health-conscious citizens, and a high level of healthcare expenditure.
Asia-Pacific will grow at the fastest CAGR during the forecast period. Cancer rates are rising in low- and middle-income countries in Asia-Pacific due to aging populations and lifestyle changes resulting from economic development and epidemiological transition. The growing economies of India, China, and Australia are forecast to offer significant potential for this industry.
Leading Competitors
The leading prominent companies profiled in the global oncology molecular diagnostics market are:
Scope of the Report
The global oncology molecular diagnostics market segmentation focuses on Product Type, Technology Type, Application Type, End-User, and Region.
Segmentation based on Product Type
Segmentation based on Technology Type
Segmentation based on Application Type
Segmentation based on End-User
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 INSTRUMENT
5.3 REAGENTS
5.4 OTHER
6 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY TYPE
6.1 OVERVIEW
6.2 POLYMERASE CHAIN REACTION (PCR)
6.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
6.4 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING
6.5 IN-SITU HYBRIDIZATION
6.6 MASS SPECTROMETRY
6.7 TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)
6.8 CHIPS AND MICROARRAYS
6.9 OTHER TECHNOLOGY TYPES
7 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION TYPE
7.1 OVERVIEW
7.2 BREAST CANCER
7.3 PROSTATE CANCER
7.4 COLORECTAL CANCER
7.5 LUNG CANCER
7.6 BLOOD CANCER
7.7 LIVER CANCER
7.8 CERVICAL CANCER
7.9 OTHER APPLICATION TYPES
8 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END-USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 DIAGNOSTIC CENTERS
8.4 OTHERS
9 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3. 1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
11 COMPANY PROFILES
11.1 ABBOTT LABORATORIES
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.2 F. HOFFMANN LA-ROCHE LIMITED
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.3 DANAHER CORPORATION (CEPHEID)
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.4 SYSMEX CORPORATION (SYSMEX EUROPE GMBH)
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.5 ILLUMINA, INCORPORATED
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.6 THERMO FISHER SCIENTIFIC INCORPORATED
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.7 BIOMÉRIEUX SA
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.8 VERACYTE INCORPORATED
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.9 AGILIENT TECHNOLOGIES INCORPORATED
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.10 TBG DIAGNOSTICS LIMITED
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.11 HTG MOLECULAR DIAGNOSTICS INCORPORATED
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
11.12 QIAGEN
11.12.1 OVERVIEW
11.12.2 FINANCIAL PERFORMANCE
11.12.3 PRODUCT OUTLOOK
11.12.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved